5van Nunen AB;Hansen BE;Suh Dj.Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B:relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine am inotransferase,2003(03).
6Harris JM;Martin NE;Modim.Pegylation:a novel process for modifying pharmacokinetics[J],2001(07).
3[1]Laso FJ, lglesias Osma C, Ciudad J, et al. Chronic alcoholism is associated with an imbalanced production of Th-l/Th-2 cytokines by peripheral blood T cells. Alcohol Clin Exp Res, 1999,23 (8): 1306-11
4[2]Sakaida I, Nagatomi A, Hironaka K, et al. Quantitative analysis of liver fibrosis and stellate cell changes in patients with chronic hepatitis C after interferon therapy. Am J Gastroenterol, 1999,94(2) :489-96
5[3]Willson RA, Fischer SH, Ochs HD. Long-term interferon alpha maintenance therapy for chronic hepatitis C infection in a patient with common variable immune deficiency. J Clin Gastroenterol, 1999,29 (2): 203-6
6[4]Ishibashi K, Kashiwagi T, Ito A, et al. Changes in serum fibrogenesis markers during interferon therapy for chronic hepatitis type C. Hepatology, 1996,24 (1):27-31
7[5]Beichard O, Glaumann H, Fry den A, et al. Long-term follow-up of chronic hepatitis C patients with sustained virological response to α-interferon. J Hepatol, 1999,30(5) :783-7
8[6]Numaguchi S, Okuno M, Moriwaki H, et al. Modulation of collagen synthesis and degradation by retinoids and cytokines in 3T3 L1 preadipocytes. Intern Med, 1994,33(6) :309-16
9[7]Moreno MG, Muriel P. Remission of liver fibrosis by interferon-alpha 2b. Biochem Pharmacol, 1995,50(4) :515-20
10[8]Fabris P,Marranconi F,Bozzola L,et al. Fibrogenesis serum markers in patients with chronic hepatitis C treated with alpha-IFN. J Gastroenterol, 1999,34(3) :345-50
